Silo Pharma announces European patent grant for SPC-15, a novel PTSD preventative treatment targeting serotonin receptors.
Quiver AI Summary
Silo Pharma has received a patent from the European Patent Office for its lead candidate, SPC-15, an innovative intranasal treatment aimed at preventing stress-induced psychiatric disorders like PTSD before they occur. This patent, which Silo exclusively licensed from Columbia University, covers methods of using serotonin 4 receptor agonists to prevent depressive-like behaviors related to extreme stress exposure. CEO Eric Weisblum highlighted the significance of this preventative approach, noting that it could revolutionize how at-risk individuals are protected from developing PTSD and related disorders. The patent enhances Silo's intellectual property portfolio and complements other global patent protections for SPC-15. The company, focused on biopharmaceutical advancements and AI technology, is dedicated to developing treatments for underserved conditions.
Potential Positives
- Granting of the European patent strengthens Silo Pharma's intellectual property portfolio for its lead candidate SPC-15, which focuses on preventing stress-induced psychiatric disorders.
- The patent recognition from the European Patent Office underscores the novelty of Silo's therapeutic approach targeting pathways associated with stress resilience.
- Silo Pharma's exclusive license for the patent from Columbia University enhances its capacity to develop and commercialize SPC-15 in the European market.
Potential Negatives
- The press release relies heavily on forward-looking statements, which include inherent risks and uncertainties, potentially undermining investor confidence in the company's projections and plans.
- The company's focus on developmental-stage products in a highly competitive biopharmaceutical market may raise concerns about its ability to successfully bring its therapies, such as SPC-15, to market.
- There is an implicit reliance on external collaborations, such as the licensing agreement with Columbia University, which could pose challenges in terms of dependency on third parties for development and commercialization efforts.
FAQ
What is SPC-15 and its intended use?
SPC-15 is a novel intranasal treatment aimed at preventing post-traumatic stress disorder (PTSD) and stress-induced psychiatric disorders.
What recent patent was granted for SPC-15?
The European Patent Office has granted patent EP3952852 covering preventative methods of treating stress-induced disorders with serotonin 4 receptor agonists.
How does SPC-15 differ from traditional PTSD treatments?
SPC-15 targets stress resilience pathways to prevent PTSD rather than solely managing symptoms after the disorder develops.
Who holds the exclusive license for SPC-15?
Silo Pharma holds an exclusive license agreement with Columbia University to develop, manufacture, and commercialize SPC-15 globally.
What broader strategy does Silo Pharma pursue?
Silo Pharma aims to expand into high-growth technology markets while advancing its biopharmaceutical pipeline addressing underserved conditions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SILO Hedge Fund Activity
We have seen 8 institutional investors add shares of $SILO stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRW SECURITIES, LLC removed 333,733 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $120,043
- GEODE CAPITAL MANAGEMENT, LLC added 87,126 shares (+93.8%) to their portfolio in Q1 2026, for an estimated $31,339
- ADVISORSHARES INVESTMENTS LLC added 64,458 shares (+10.8%) to their portfolio in Q1 2026, for an estimated $23,185
- XTX TOPCO LTD removed 39,816 shares (-70.0%) from their portfolio in Q1 2026, for an estimated $14,321
- FNY INVESTMENT ADVISERS, LLC added 37,507 shares (+inf%) to their portfolio in Q2 2026, for an estimated $232,918
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 33,218 shares (+112.3%) to their portfolio in Q1 2026, for an estimated $11,948
- CITADEL ADVISORS LLC added 21,448 shares (+inf%) to their portfolio in Q1 2026, for an estimated $7,714
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms develop
SARASOTA, FLA., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a managed AI agent platform and developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the European Patent Office (EPO) has granted a patent covering the preventative approach of its lead candidate SPC-15, a novel intranasal, nose-to-brain treatment targeting post-traumatic stress disorder (PTSD) and stress-induced affective disorders. The Company has an exclusive license for the European patent from Columbia University.
The granted patent, European Patent No. EP3952852, “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” covers methods of preventing stress-induced fear, depressive-like behavior and associated affective disorders by administering selected serotonin 4 (5-HT4) receptor agonists ahead of a stressor such as potential extreme stress exposure.
“We continue to strengthen the powerful intellectual property moat around SPC-15’s technology—a differentiated approach to PTSD treatment that targets pathways associated with stress resilience rather than relying solely on symptom management after PTSD has developed,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “We are pleased with the EPO’s decision recognizing the novelty of this preventative approach and extending important patent protection for SPC-15 in the European market. We believe the ability to intervene before exposure to acute trauma could represent an entirely new paradigm for protecting individuals at high risk of developing PTSD and other stress-related disorders.”
The new European patent further expands the intellectual property portfolio supporting SPC-15 and complements patent protection granted and pending in five other major global markets.
Silo holds an exclusive license agreement with Columbia University to further develop, manufacture, and commercialize SPC-15 globally.
About Silo Pharma, Inc.
QwikAgents , Silo Pharma's wholly owned artificial intelligence subsidiary, is a managed AI agent platform that delivers dedicated autonomous agents for research, content generation, scheduling, and workflow automation — each running in a persistent environment with proprietary smart-routing across multiple AI models. The subsidiary reflects Silo's strategy to expand into high-growth technology markets while continuing to advance its core biopharmaceutical pipeline. qwikagents.com
Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
(800) 705-0120
[email protected]
